EWING, NJ--(Marketwire - July 18, 2008) - DOR BioPharma, Inc. (OTCBB: DORB) ("DOR" or the "Company"), a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines against certain bioterrorism agents, announced today that it has entered into a collaboration with Steward Cross Pte Ltd (Steward Cross), a specialty pharmaceutical company based in Singapore, under which Steward Cross will act as DOR's Sponsor with regard to the administration of a Named Patient Access Program (NPAP) for orBec® to patients suffering from acute gastrointestinal Graft-versus-Host disease (GI GVHD) in Singapore and Malaysia.
